DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market sentiment turned positive.

The upward movement appears to be driven by a combination of positive analyst actions and strategic product developments. Multiple financial institutions issued favorable research notes on DexCom, including Mizuho raising its price target to $90 from $78 and Barclays increasing its target to $72 from $71. Other firms including Morgan Stanley, Bernstein, and BTIG maintained their positive ratings on the stock.

Additionally, DexCom announced the expansion of AI-enabled features for its Stelo over-the-counter glucose biosensor, adding expanded Smart Food Logging and a broad nutrition database. This strategic move deepens the company's push into consumer-focused digital health and comes after the company reported better-than-expected Q4 2025 results, with sales reaching US$1.26 billion for the quarter.